Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via Google Scholar Articles by Amdur, M. A. Search for Related Content PubMed Citation Articles by Amdur, M. A. Confidentiality Other Ethics Issues Hospitals, Hospital Treatment Schizophrenia Spectrum Disorders Stress Other Violence/Aggression Atypical Neuroleptics Related Article

Impractical Features of Long-Acting Risperidone

Obtaining long-acting risperidone is complicated and time-consuming. There is a paperwork burden associated with procurement of the drug. Storage and administration of long-acting risperidone is cumbersome and time-consuming. The drug must be refrigerated. Our agency receives the drug at multiple sites, and it is handled by multiple persons. The chain of custody must be ensured. Assembling the components of the injection system takes time and dexterity. The actual cost of the drug includes the drug itself—about $500 a month—plus increased cost to insurers because of the necessity of more clinic visits by patients who are receiving the drug plus nonreimbursable clerical costs to the clinic.

Unless the mental health agency has deep pockets and an experienced billing department and has prepurchased the drug, no long-acting risperidone is available for immediate use. The moment a patient says, "Yes, I'll take the shot," the physician must reply, "Great! Come back next week." This is no way to initiate treatment. In addition, because gluteal injection is required, I cannot be alone with my female patients or my homophobic male patients.

There are significant disincentives to the use of long-acting risperidone that should have been anticipated and considered by the manufacturer. I believe that the underutilization of fluphenazine and haloperidol decanoate had more to do with physician reluctance than patient reluctance. The cost and the problems with storage and use of long-acting risperidone are daunting obstacles for a community practitioner who is not surrounded by a bevy of nurses and clerks.

A journal that once contained the word "community" in its title should be taking a lead in demanding pharmacologic treatments that are not simply effective but also accessible.

Mark A. Amdur, M.D.

Footnotes

Dr. Amdur is medical director of Thresholds in Chicago.

References

1. Keith SJ, Pani L, Nick B, et al: Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatric Services 55:997–1005, 2004[Abstract/Free Full Text]

Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via Google Scholar Articles by Amdur, M. A. Search for Related Content PubMed Citation Articles by Amdur, M. A. Confidentiality Other Ethics Issues Hospitals, Hospital Treatment Schizophrenia Spectrum Disorders Stress Other Violence/Aggression Atypical Neuroleptics Related Article

Get information about faster international access.

Privacy Policy

Copyright © 2004 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us